IMV News and Press, IMV Inc. From 05/16/22

The following slide deck was published by IMV Inc. in conjunction with their 2022 Q1 earnings call. For further details see: IMV Inc. 2022 Q1 - Results - Earnings Call Presentation

IMV Inc. (IMV) Q1 2022 Earnings Conference Call May 13, 2022, 8:00 AM ET Company Participants Andrew Hall – Chief Executive Officer Jeremy Graff – Chief Medical Officer Brittany Davison – Senior Vice President, Finance Joy Bessenger – Senior Vice President, Investo...

IMV press release (NASDAQ:IMV): Q1 GAAP EPS of -$0.13 beats by $0.01. Revenue of $0.03M (-57.1% Y/Y) in-line. For further details see: IMV GAAP EPS of -$0.13 beats by $0.01, revenue of $0.03M in-line

Positive clinical results in bladder cancer were presented at the AACR annual meeting, including 2 confirmed complete responses (CRs) and 3 partial responses (PRs) per RECIST v1.1; CRs and PRs were observed in patients previously treated with checkpoint inhibitors; Tre...

CCLP, CWCO, OTCQX:DTEGY, OTCPK:EMRAF, HIPO, HMC, HNST, HUMA, IMV, LFMD, MUX, OTLK, VLTA, ZEV For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings before Friday's open

IMV Inc. (Nasdaq: IMV; TSX: IMV) (“IMV” or “the Company”), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid and hematologic cancers, today announced that it will hold a conference cal...

IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, today announced the Company’s lead compound, maveropepimut-S (MVP-S), will be showcased in...

IMV (NASDAQ:IMV) has appointed Michael P. Bailey, President and Chief Executive Officer of AVEO Oncology as Chairman of the Board, effective May 1, 2022. Mr. Bailey has served on the company's Board of Directors since 2020 and chairs the governance committee, as well as serving as a memb...

IMV Inc. (Nasdaq: IMV; TSX: IMV) (“IMV” or “the Company”), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid and hematologic cancers, today announced that its Board of Directors has el...

Combination of MVP-S/CPA and pembrolizumab showed encouraging clinical activity in advanced, metastatic bladder cancer patients, particularly in patients who had received prior immune checkpoint inhibitor therapy The combination treatment was well-tolerated with adverse events...